Business Context and Reporting Period
This Form 8-K, dated April 4, 2019, reports on litigation developments and supplemental disclosures regarding the proposed merger between Bristol-Myers Squibb Company ("BMS") and Celgene Corporation ("Celgene"). The filing addresses a settlement with a BMS shareholder plaintiff to dismiss claims alleging failure to disclose material information about the merger.
Key Financial Metrics and Transaction Details
The filing provides specific financial data related to the merger valuation and advisory fees rather than standard operating results for a reporting period.
- Advisory Fees: BMS agreed to pay Morgan Stanley $15 million upon announcement and $67 million upon consummation for financial advisory services. An additional $100 million is payable for financing and liability management services, plus approximately $5.3 million for an interest rate swap option.
- Celgene Net Debt: Estimated at $16.2 billion as of December 31, 2018, including a $1.5 billion tax repatriation liability.
- BMS Net Debt: Estimated at ($0.7) billion (net cash position) as of December 31, 2018, including a $2.1 billion tax repatriation liability.
- Transaction Consideration: Estimated cash consideration to Celgene stockholders is $37 billion. The filing also notes an expected $5 billion share repurchase by BMS post-merger and a probability-adjusted net present value of $2 billion for the Contingent Value Right (CVR).
- Valuation Ranges (DCF Analysis):
- Celgene stand-alone implied equity value: $95 to $136 per share (mid-point $112).
- BMS stand-alone implied equity value: $64 to $79 per share (mid-point $71).
- Projected Synergies: $21 billion to $26 billion.
Material Changes and Litigation Status
The primary material event is the resolution of the Landers lawsuit filed by BMS shareholders. On April 4, 2019, BMS and the plaintiff entered a memorandum of understanding where the plaintiff agreed to dismiss claims with prejudice in exchange for the supplemental disclosures contained in this filing. The filing explicitly states these disclosures are made to moot the claims and avoid litigation delays, not as an admission of legal necessity.
Additionally, the filing notes ongoing litigation by Celgene stockholders. As of April 4, 2019, three complaints naming BMS and eight complaints not naming BMS have been filed seeking to enjoin the merger, alleging incomplete or misleading information in the proxy materials.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the merger's anticipated benefits, synergy realization, and integration. Management emphasizes that projected financial information is based on estimates and assumptions and has not been prepared in conformance with Regulation S-X pro forma requirements.
Key Risks Disclosed:
- Failure to satisfy closing conditions or obtain regulatory approvals.
- Inability to achieve projected synergies or effectively integrate Celgene.
- Diversion of management attention and operational disruption.
- Potential decline in credit ratings of the combined company.
- Legal proceedings and uncertainties regarding patent positions and product development.
Investor Verification Checklist
- Verify the final terms of the merger agreement and the status of regulatory approvals.
- Review the definitive joint proxy statement/prospectus (filed February 22, 2019) for the complete context of the supplemental disclosures.
- Monitor the status of the eleven federal complaints filed by Celgene stockholders seeking to enjoin the merger.
- Assess the assumptions used in the DCF analysis, specifically the perpetual growth rates (0.5% to 2.0% for Celgene; -1.0% to 0.0% for BMS) and discount rates (7.5% to 9.0% for Celgene; 7.5% to 8.5% for BMS).
- Confirm the actual costs incurred for Morgan Stanley's services upon merger consummation.